Stockscreener 앱 받기
5.50
4.18%
-0.24
시장 영업 전:
5.52
0.02
+0.36%
Immuneering Corp 주식(IMRX)의 최신 뉴스
Immuneering To Initiate Phase 3 Atebimetinib Trial In Pancreatic Cancer In Mid-2026 - Nasdaq
Immuneering to begin Phase 3 trial of pancreatic cancer drug mid-2026 By Investing.com - Investing.com South Africa
Immuneering stock rises after FDA and EMA align on Phase 3 trial design - Investing.com
Immuneering to begin Phase 3 trial of pancreatic cancer drug mid-2026 - Investing.com Canada
Immuneering on track to dose first patient in pancreatic cancer trial in 2026 - TipRanks
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA - The Manila Times
Immuneering Corporation Completes FDA EOP2 Interactions and Prepares for Global Phase 3 Trial of Atebimetinib in Pancreatic Cancer - Quiver Quantitative
Global trial to test drug combo for first-line pancreatic cancer patients - Stock Titan
Immuneering to be added to the Nasdaq Biotechnology Index - TipRanks
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) - The Manila Times
Immuneering Corporation (NASDAQ:IMRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Top investors say Immuneering Corp (IMRX) ticks everything they need - setenews.com
This trade activity should not be overlooked: Immuneering Corp (IMRX) - setenews.com
Immuneering (IMRX) Stock Analysis Report | Financials & Insights - Benzinga
We Think Immuneering (NASDAQ:IMRX) Can Afford To Drive Business Growth - Yahoo Finance
Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High? - Yahoo Finance
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Immuneering Corporation (IMRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
A new trading data show Immuneering Corp (IMRX) is showing positive returns. - Setenews
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth - Sahm
Combining machine learning predictions for Immuneering Corporation2025 Technical Overview & Technical Pattern Based Signals - newser.com
Best data tools to analyze Immuneering Corporation stockTrend Reversal & Stepwise Trade Execution Plans - newser.com
How Immuneering Corporation stock compares to growth peersLong Setup & Reliable Breakout Stock Forecasts - newser.com
Is Immuneering Corporation stock poised for growthBear Alert & Community Trade Idea Sharing - newser.com
Does Immuneering Corporation qualify in momentum factor screeningMarket Growth Review & Step-by-Step Trade Execution Guides - newser.com
Can Immuneering Corporation stock reach $100 price targetEntry Point & Long-Term Safe Investment Plans - newser.com
Will Immuneering Corporation stock beat EPS estimatesPortfolio Gains Report & High Win Rate Trade Alerts - newser.com
Can machine learning forecast Immuneering Corporation recoveryMarket Volume Report & Entry Point Confirmation Signals - newser.com
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Is Immuneering Corporation stock undervalued vs historical averages2025 Valuation Update & Real-Time Stock Movement Alerts - newser.com
What data driven models say about Immuneering Corporation’s futureMarket Activity Summary & Safe Entry Point Alerts - newser.com
Why Immuneering Corporation stock is recommended by analystsWeekly Market Outlook & Fast Exit and Entry Trade Guides - newser.com
Can momentum traders help lift Immuneering CorporationJuly 2025 Analyst Calls & Advanced Technical Analysis Signals - newser.com
Immuneering Corporation (NASDAQ:IMRX) Q3 2025 Earnings Call Transcript - Insider Monkey
Immuneering Corp. Shines in Positive Earnings Call - TipRanks
What momentum indicators show for Immuneering Corporation stockWeekly Stock Report & High Return Trade Guides - newser.com
0.18%
0.62%
자본화:
|
볼륨(24시간):